bevacizumab (Avastin, Genentech)

ALG-1001: Turning off the machinery of angiogenesisALG-1001 (Luminate, Allegro Ophthalmics) has a number of different mechanisms of action that benefit patients chronically treated with anti-vascular endothelial growth factor drugs and those who are treatment naïve.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
Pros and cons of compounded pharmaceuticalsCompounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
Access, costs of bevacizumab key factors for DME therapyThe efficacy of intravitreal bevacizumab (Avastin, Genentech) for improving vision in patients with center-involving diabetic macular edema (DME) has been demonstrated in several clinical trials.
Research limited on role of combination therapy for CRVO-related MECombination therapy may be a reasonable approach to manage eyes that are not responding to intravitreal monotherapy with an anti-vascular endothelial growth factor (VEGF) agent or corticosteroid, said Lihteh Wu, MD, at the inaugural Retina World Congress.
Bevacizumab 6-week AMD regimen falls short of ranibizumab 4-week regimen
Observations may provide evidence of systemic effect of anti-VEGF therapyIntravitreal aflibercept may be associated with systemic effects based on an observable reaction in the fellow eyes of patients with diabetic macular edema.
Novartis deterred UK physicians from prescribing Avastin, report saysNovartis attempted to block studies in the United Kingdom comparing ranibizumab (Lucentis) and bevacizumab (Avastin) for the treatment of wet age-related macular degeneration (AMD), according to an article published in The BJM, an international peer-reviewed medical journal.
Comparing anti-VEGFs for DMEIn a 1-year comparison of intravitreous aflibercept, bevacizumab and ranibizumab therapy for centre-involved DME, aflibercept was more effective at improving vision among patients who started treatment at lower levels of visual acuity.
Switching treatments for wet AMD poses numerous complexities
Switching treatments for wet AMD poses numerous complexitiesStudies that focus on switching treatments for exudative age-related macular degeneration may represent more real-life scenarios. However, future prospective studies with predetermined switching criteria and follow-up are needed.